Skip to main content
. 2019 Dec 2;9:18042. doi: 10.1038/s41598-019-54529-9

Table 1.

Study characteristics.

Author Recruitment site Design Study period Sample size (Intervention/Control) Intervention(s) Comparison(s) Measurement tools
Breakdown Total (for each participant) Full analysis set Per-protocol Outcome Compliance Safety and tolerability

Woelk & Schlafke (2009)35

Germany

General practitioner’s clinics Multi-centre, double-blind, randomised phase III study 1 week screening phase, 6 weeks treatment phase, 2 weeks discontinuation phase. 9 weeks 40/37 36/33 80 mg Silexan capsule + Lorazepam placebo once daily during 6-week treatment phase, and on day 43,45,47,50 and 53 during the discontinuation phase. 0.5 mg Lorazepam capsule + Silexan placebo once daily during 6-week treatment phase, and on day 43,45,47,50 and 53 during the discontinuation phase. Hamilton Anxiety Rating Scale (HAMA total score) Method was not reported Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements

Kasper et al. (2015)38

Germany

17 general and psychiatric practices Randomized, double-blind trial Single-blind screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Post-baseline efficacy and safety assessments performed every 2 weeks 11 weeks 86/84 73/65 80 mg Silexan capsule once daily Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily Hamilton Anxiety Rating Scale (HAMA total score) Compared the number of unused capsules returned by the patients to the expected number assuming a fully protocol compliant intake Adverse events (AE) reported spontaneously, physical and ECG examinations, vital signs, routine laboratory measurements

Kasper, et al. (2016)39

Germany

35 psychiatric practices Double-blind, randomized, placebo-controlled, parallel-group multicentre trial Screening period of 3–7 days, followed by 10 weeks treatment phase. Efficacy and safety assessments performed at 1 and 2 weeks ± 2 days, as well as at 4, 7 and 10 weeks ± 7 days after baseline 11 weeks 159/156 141/128 80 mg Silexan capsule once daily Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily Hamilton Anxiety Rating Scale (HAMA total score) Assessed by counting of returned medication Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements

Kasper, et al. (2014)37

Germany

57 psychiatric and general practices Randomized, double-blind, double-dummy, multi-centre trial with four parallel groups Screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Efficacy and safety assessments performed after 2, 4, 6, 8 and 10 weeks. Treatment phase is followed by 1 week down-titration phase for paroxetine withdrawal 12 weeks 121 (Silexan 160 mg/d)/13 5 (Silexan 80 mg/d)/132 (paroxetine)/135 (placebo) 103 (Silexan 160 mg/d)/119 (Silexan 80 mg/d)/114 (paroxetine)/114 (placebo) 160 mg Silexan capsule once daily; 80 mg Silexan capsule once daily. 20 mg Paroxetine capsule; placebo capsule. Hamilton Anxiety Rating Scale (HAMA total score) Assessed by medication counting Adverse events (AE) reported spontaneously, physical examinations, routine laboratory measurements. Withdrawal symptoms ascertained by administering the Physician Withdrawal Checklist (PWC-20) at the end of treatment phase and down-titration phase.

Kasper, et al. (2010)36

Germany

27 general and psychiatric primary care centres Randomized, double-blind, placebo controlled, multi-centre trial Single-blind placebo screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Post-baseline efficacy and safety assessments performed every 2 weeks 12 weeks 104/108 87/90 80 mg Silexan capsule daily Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily Hamilton Anxiety Rating Scale (HAMA total score) Method was not reported Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements